-
-
-
-
Description
- Indolicidin based
-
Activity
- Antibacterial, Antifungal
-
Medical use
- the treatment of catheter-related acne
-
Stage of Development
- Phase IIb(Completed)
-
- MX-594AN significantly reduced acne lesions compared with vehicle controls in a phase IIb trial in 2003 and was licensed to Cutanea Life Sciences in late 2005.
-
Company
- Migenix (Vancouver, BritishColumbia, Canada)
-
Target Organism
-
- No MICs found on DRAMP database
-
Reference
-
- Cationic antimicrobial peptides in clinical development, with special focus on thanatin and heliomicin.Eur J Clin Microbiol Infect Dis (2012)(PMID: 21964560)